Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Aryeh Blumenreich"'
Autor:
Lauren Laderman, Krishnalatha Sreekrishnanilayam, Ramesh K. Pandey, Elizabeth Handorf, Aryeh Blumenreich, Kristen A. Sorice, Shannon M. Lynch, Khadija Cheema, Lavanya Nagappan, Iberia R. Sosa, Efrat Dotan, Namrata Vijayvergia
Publikováno v:
European Journal of Haematology. 110:706-714
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96002be3e69b7de86fc6a0ff6015677d
https://doi.org/10.1111/ejh.13955
https://doi.org/10.1111/ejh.13955
Autor:
Efrat Dotan, Emily Walzer, Lauren Pease, Namrata Vijayvergia, Mengying Deng, Aryeh Blumenreich, Kristen Sorice, Elizabeth Handorf, Marianna Dorta, Shannon M. Lynch
Publikováno v:
Journal of Clinical Oncology. 38:672-672
672 Background: PC affects 57,000 people in the U.S. annually with poor long-term outcomes. NAT for localized disease has increasingly been used but lacks robust prospective data. We investigated the disease course and outcomes for patients (pts) und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48310fe1d9ff233b07447ff77d6e6c26
https://doi.org/10.1200/jco.2020.38.4_suppl.672
https://doi.org/10.1200/jco.2020.38.4_suppl.672
Autor:
Khadija Cheema, Aryeh Blumenreich, Ramesh Kumar Pandey, Lavanya Nagappan, Kristen Sorice, Jiangtao Gou, Efrat Dotan, Shannon M. Lynch, Namrata Vijayvergia
Publikováno v:
Journal of Clinical Oncology. 37:232-232
232 Background: The incidence of VTE is relatively high among mPC pts, upto 57%. It is associated with higher health care burden and mortality. We evaluated the mPC pts treated at a single academic center from 2010-16 for prevalence of VTE, its impac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::50d621092e7187e8e243b032a8c1eed9
https://doi.org/10.1200/jco.2019.37.4_suppl.232
https://doi.org/10.1200/jco.2019.37.4_suppl.232
Autor:
Farhana Chowdhury, Lavanya Nagappan, Efrat Dotan, Aryeh Blumenreich, Elizabeth Handorf, Arthur Winer, Namrata Vijayvergia
Publikováno v:
Journal of Clinical Oncology. 37:358-358
358 Background: The median age at diagnosis for metastatic pancreatic cancer (mPC) is 72. Gemcitabine and Nab-Paclitaxel (GA) is often the preferred chemo regimen in this population due to presumed reduced toxicity compared with FOLFIRINOX. While the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ea5f8d36d54c86689e991836b05ae59
https://doi.org/10.1200/jco.2019.37.4_suppl.358
https://doi.org/10.1200/jco.2019.37.4_suppl.358